Primary effusion lymphoma occurring in the setting of transplanted patients: a systematic review of a rare, life-threatening post-transplantation occurrence.
Bone Marrow Transplantation
Diagnosis, Differential
Heart Transplantation
Herpesviridae Infections
/ immunology
Herpesvirus 8, Human
/ immunology
Humans
Immunocompromised Host
Intestines
/ transplantation
Kidney Transplantation
Liver Transplantation
Lymphoma, Primary Effusion
/ epidemiology
Postoperative Complications
/ epidemiology
Rare Diseases
/ epidemiology
Sarcoma, Kaposi
Transplant Recipients
Effusion
Epstein-Barr virus
Human Herpesvirus 8
Lymphoma
Transplantation
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
27 Apr 2021
27 Apr 2021
Historique:
received:
30
12
2020
accepted:
19
04
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Primary effusion lymphoma is a rare, aggressive large B-cell lymphoma strictly linked to infection by Human Herpes virus 8/Kaposi sarcoma-associated herpes virus. In its classic form, it is characterized by body cavities neoplastic effusions without detectable tumor masses. It often occurs in immunocompromised patients, such as HIV-positive individuals. Primary effusion lymphoma may affect HIV-negative elderly patients from Human Herpes virus 8 endemic regions. So far, rare cases have been reported in transplanted patients. The purpose of our systematic review is to improve our understanding of this type of aggressive lymphoma in the setting of transplantation, focusing on epidemiology, clinical presentation, pathological features, differential diagnosis, treatment and outcome. The role of assessing the viral serological status in donors and recipients is also discussed. We performed a systematic review adhering to the PRISMA guidelines. The literature search was conducted on PubMed/MEDLINE, Web of Science, Scopus, EMBASE and Cochrane Library, using the search terms "primary effusion lymphoma" and "post-transplant". Our search identified 13 cases of post-transplant primary effusion lymphoma, predominantly in solid organ transplant recipients (6 kidney, 3 heart, 2 liver and 1 intestine), with only one case after allogenic bone marrow transplantation. Long-term immunosuppression is important in post-transplant primary effusion lymphoma commonly developing several years after transplantation. Kaposi Sarcoma occurred in association with lymphoma in 4 cases of solid organ recipients. The lymphoma showed the classical presentation with body cavity effusions in absence of tumor masses in 10 cases; 2 cases presented as solid masses, lacking effusions and one case as effusions associated with multiple organ involvement. Primary effusion lymphoma occurring in the setting of transplantation was more often Epstein Barr-virus negative. The prognosis was poor. In addition to chemotherapy, reduction of immunosuppressive treatment, was generally attempted. Primary effusion lymphoma is a rare, but often fatal post-transplant complication. Its rarity and the difficulty in achieving the diagnosis may lead to miss this complication. Clinicians should suspect primary effusion lymphoma in transplanted patients, presenting generally with unexplained body cavity effusions, although rare cases with solid masses are described.
Sections du résumé
BACKGROUND
BACKGROUND
Primary effusion lymphoma is a rare, aggressive large B-cell lymphoma strictly linked to infection by Human Herpes virus 8/Kaposi sarcoma-associated herpes virus. In its classic form, it is characterized by body cavities neoplastic effusions without detectable tumor masses. It often occurs in immunocompromised patients, such as HIV-positive individuals. Primary effusion lymphoma may affect HIV-negative elderly patients from Human Herpes virus 8 endemic regions. So far, rare cases have been reported in transplanted patients. The purpose of our systematic review is to improve our understanding of this type of aggressive lymphoma in the setting of transplantation, focusing on epidemiology, clinical presentation, pathological features, differential diagnosis, treatment and outcome. The role of assessing the viral serological status in donors and recipients is also discussed.
METHODS
METHODS
We performed a systematic review adhering to the PRISMA guidelines. The literature search was conducted on PubMed/MEDLINE, Web of Science, Scopus, EMBASE and Cochrane Library, using the search terms "primary effusion lymphoma" and "post-transplant".
RESULTS
RESULTS
Our search identified 13 cases of post-transplant primary effusion lymphoma, predominantly in solid organ transplant recipients (6 kidney, 3 heart, 2 liver and 1 intestine), with only one case after allogenic bone marrow transplantation. Long-term immunosuppression is important in post-transplant primary effusion lymphoma commonly developing several years after transplantation. Kaposi Sarcoma occurred in association with lymphoma in 4 cases of solid organ recipients. The lymphoma showed the classical presentation with body cavity effusions in absence of tumor masses in 10 cases; 2 cases presented as solid masses, lacking effusions and one case as effusions associated with multiple organ involvement. Primary effusion lymphoma occurring in the setting of transplantation was more often Epstein Barr-virus negative. The prognosis was poor. In addition to chemotherapy, reduction of immunosuppressive treatment, was generally attempted.
CONCLUSIONS
CONCLUSIONS
Primary effusion lymphoma is a rare, but often fatal post-transplant complication. Its rarity and the difficulty in achieving the diagnosis may lead to miss this complication. Clinicians should suspect primary effusion lymphoma in transplanted patients, presenting generally with unexplained body cavity effusions, although rare cases with solid masses are described.
Identifiants
pubmed: 33906629
doi: 10.1186/s12885-021-08215-7
pii: 10.1186/s12885-021-08215-7
pmc: PMC8077837
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
468Références
N Engl J Med. 1998 Aug 13;339(7):444-9
pubmed: 9700178
Am J Transplant. 2015 Oct;15(10):2762-6
pubmed: 25988353
BMC Cancer. 2019 Sep 13;19(1):916
pubmed: 31519155
Semin Cancer Biol. 1999 Jun;9(3):175-85
pubmed: 10343069
Br J Haematol. 2019 May;185(3):397
pubmed: 30729504
Br J Haematol. 2019 Dec;187(5):555
pubmed: 31515799
Adv Anat Pathol. 2020 Mar;27(2):61-74
pubmed: 31725418
Transpl Infect Dis. 2019 Feb;21(1):e13005
pubmed: 30276937
Am J Transplant. 2008 Apr;8(4):906-7
pubmed: 18294348
Blood. 2012 Nov 15;120(20):4150-9
pubmed: 22968461
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879
Cytopathology. 2012 Apr;23(2):137-9
pubmed: 22335200
Blood. 1995 Aug 15;86(4):1276-80
pubmed: 7632932
Leukemia. 1999 May;13(5):664-70
pubmed: 10374868
Leuk Lymphoma. 2002 Mar;43(3):517-22
pubmed: 12002754
Ann Hematol. 2019 Oct;98(10):2439-2441
pubmed: 31377818
Transplant Proc. 2010 Nov;42(9):3849-53
pubmed: 21094868
Histopathology. 2018 Jan;72(2):339-341
pubmed: 28815752
Clin Transplant. 2019 Sep;33(9):e13518
pubmed: 30844089
Am J Transplant. 2008 Mar;8(3):707-10
pubmed: 18261181
Heart Lung. 2014 Nov-Dec;43(6):506-9
pubmed: 25169666
N Engl J Med. 1995 May 4;332(18):1186-91
pubmed: 7700311
Autops Case Rep. 2020 Nov 20;10(4):e2020206
pubmed: 33344322
Ann Hematol. 2020 Oct;99(10):2243-2253
pubmed: 32307569
Diagn Cytopathol. 2015 Feb;43(2):144-8
pubmed: 24644156
Bone Marrow Transplant. 2012 Sep;47(9):1250-1
pubmed: 22246087